RPS20P12

Across TCGA pan-cancer cohorts, RPS20P12 RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of RPS20P12’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where RPS20P12 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RPS20P12 is over-expressed in tumor, although a few such as PAAD and LUSC show the opposite, repressed pattern.

KIRC, BLCA, and PAAD are the cancer types where RPS20P12 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPS20P12 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	All	III,IV	+0.211	<.001	10	view →
BLCA	Female	All	+0.268	.021	3	view →
PAAD	Female	All	−0.625	.044	2	view →
LUAD	Female	All	+0.240	.004	2	view →
LUSC	Female	All	−0.167	.014	2	view →
HNSC	Male	II,III,IV	+0.112	.014	2	view →
THCA	Female	II,III,IV	+0.240	.017	1	view →
COAD	All	III,IV	+0.174	.044	1	view →
KICH	Male	III,IV	−0.125	.024	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

RPS20P12–KIRC

Open the KIRC breakdown →